PAG1 Antibody (C-Terminus, clone PAG-C1)
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, IP |
---|---|
Primary Accession | Q9NWQ8 |
Reactivity | Human, Mouse, Rat, Bovine |
Host | Mouse |
Clonality | Monoclonal |
Clone Names | PAG-C1 |
Calculated MW | 47kDa |
Dilution | IHC-P (15 µg/ml) |
Gene ID | 55824 |
---|---|
Other Names | Phosphoprotein associated with glycosphingolipid-enriched microdomains 1, Csk-binding protein, Transmembrane adapter protein PAG, Transmembrane phosphoprotein Cbp, PAG1, CBP, PAG |
Target/Specificity | Recognizes an epitope located in the C-terminal domain of Csk-binding protein (Cbp / PAG), a 46 kD ubiquitously expressed transmembrane adaptor protein present in membrane rafts (glycosphingolipid-enriched microdomains), which however migrates on SDS ... |
Reconstitution & Storage | +4°C or -20°C, Avoid repeated freezing and thawing. |
Precautions | PAG1 Antibody (C-Terminus, clone PAG-C1) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | PAG1 |
---|---|
Synonyms | CBP, PAG |
Function | Negatively regulates TCR (T-cell antigen receptor)-mediated signaling in T-cells and FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Promotes CSK activation and recruitment to lipid rafts, which results in LCK inhibition. Inhibits immunological synapse formation by preventing dynamic arrangement of lipid raft proteins. May be involved in cell adhesion signaling. |
Cellular Location | Cell membrane; Single-pass type III membrane protein Note=Present in lipid rafts |
Tissue Location | Ubiquitously expressed. Present in germinal center B-cells, plasma cells, T-cells, monocytes and platelets (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Negatively regulates TCR (T-cell antigen receptor)- mediated signaling in T-cells and FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Promotes CSK activation and recruitment to lipid rafts, which results in LCK inhibition. Inhibits immunological synapse formation by preventing dynamic arrangement of lipid raft proteins. May be involved in cell adhesion signaling.
References
Brdicka T.,et al.J. Exp. Med. 191:1591-1604(2000).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Brdickova N.,et al.FEBS Lett. 507:133-136(2001).
Brill L.M.,et al.Anal. Chem. 76:2763-2772(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.